Download Now: Exclusive Guide About India's Potentially Decade-Long $10 Trillion Bull Run...
Here is the latest financial fact sheet of GLAND PHARMA. For more details, see the GLAND PHARMA quarterly results and GLAND PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -0.6 |
No. of shares | m | 164.71 |
1 Week | % | -1.9 |
1 Month | % | -3.3 |
1 Year | % | 28.1 |
52 week H/L | Rs | 2,195.8/861.5 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
GLAND PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | NA | 2,784 | 4,350 | 3,556 | |
Low | Rs | NA | NA | 1,701 | 2,411 | 1,130 | |
Sales per share (Unadj.) | Rs | 1,319.7 | 169.9 | 211.7 | 269.0 | 220.6 | |
Earnings per share (Unadj.) | Rs | 291.7 | 49.9 | 60.9 | 74.1 | 47.5 | |
Diluted earnings per share | Rs | 27.4 | 46.9 | 60.5 | 73.6 | 47.4 | |
Cash flow per share (Unadj.) | Rs | 344.7 | 56.0 | 67.0 | 80.8 | 56.5 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 1,847.7 | 234.3 | 359.3 | 436.7 | 484.3 | |
Adj. book value per share | Rs | 173.8 | 220.4 | 356.9 | 433.8 | 483.1 | |
Shares outstanding (eoy) | m | 15.49 | 154.95 | 163.59 | 163.59 | 164.30 | |
Price / Sales ratio | x | 0 | 0 | 10.6 | 12.6 | 10.6 | |
Avg P/E ratio | x | 0 | 0 | 36.8 | 45.6 | 49.3 | |
P/CF ratio (eoy) | x | 0 | 0 | 33.5 | 41.8 | 41.5 | |
Price / Book Value ratio | x | 0 | 0 | 6.2 | 7.7 | 4.8 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 0 | 0 | 366,894 | 553,026 | 385,002 | |
Total wages/salary | Rs m | 2,229 | 2,777 | 3,114 | 3,386 | 4,033 |
GLAND PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 20,442 | 26,332 | 34,629 | 44,007 | 36,246 | |
Other income | Rs m | 856 | 1,392 | 1,348 | 2,239 | 2,405 | |
Total revenues | Rs m | 21,298 | 27,724 | 35,977 | 46,246 | 38,651 | |
Gross profit | Rs m | 6,863 | 9,555 | 13,022 | 15,102 | 9,683 | |
Depreciation | Rs m | 820 | 946 | 988 | 1,103 | 1,467 | |
Interest | Rs m | 36 | 72 | 34 | 52 | 74 | |
Profit before tax | Rs m | 6,864 | 9,929 | 13,348 | 16,186 | 10,546 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 2,345 | 2,200 | 3,378 | 4,069 | 2,735 | |
Profit after tax | Rs m | 4,519 | 7,729 | 9,970 | 12,117 | 7,810 | |
Gross profit margin | % | 33.6 | 36.3 | 37.6 | 34.3 | 26.7 | |
Effective tax rate | % | 34.2 | 22.2 | 25.3 | 25.1 | 25.9 | |
Net profit margin | % | 22.1 | 29.4 | 28.8 | 27.5 | 21.5 |
GLAND PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 23,575 | 28,463 | 51,236 | 58,521 | 69,008 | |
Current liabilities | Rs m | 5,327 | 3,590 | 5,125 | 5,820 | 7,291 | |
Net working cap to sales | % | 89.3 | 94.5 | 133.2 | 119.8 | 170.3 | |
Current ratio | x | 4.4 | 7.9 | 10.0 | 10.1 | 9.5 | |
Inventory Days | Days | 20 | 12 | 8 | 37 | 13 | |
Debtors Days | Days | 90 | 83 | 71 | 89 | 88 | |
Net fixed assets | Rs m | 11,651 | 12,397 | 13,724 | 19,815 | 18,767 | |
Share capital | Rs m | 155 | 155 | 164 | 164 | 165 | |
"Free" reserves | Rs m | 28,466 | 36,143 | 58,615 | 71,280 | 79,406 | |
Net worth | Rs m | 28,621 | 36,298 | 58,778 | 71,444 | 79,571 | |
Long term debt | Rs m | 50 | 41 | 39 | 38 | 33 | |
Total assets | Rs m | 35,226 | 40,860 | 64,961 | 78,336 | 87,775 | |
Interest coverage | x | 193.8 | 139.2 | 392.3 | 309.8 | 142.6 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.6 | 0.6 | 0.5 | 0.6 | 0.4 | |
Return on assets | % | 12.9 | 19.1 | 15.4 | 15.5 | 9.0 | |
Return on equity | % | 15.8 | 21.3 | 17.0 | 17.0 | 9.8 | |
Return on capital | % | 24.1 | 27.5 | 22.8 | 22.7 | 13.3 | |
Exports to sales | % | 80.8 | 82.2 | 83.8 | 79.9 | 84.4 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 16,519 | 21,635 | 29,021 | 35,145 | 30,590 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 16,519 | 21,635 | 29,021 | 35,145 | 30,590 | |
Fx outflow | Rs m | 9,583 | 7,250 | 16,878 | 17,143 | 17,819 | |
Net fx | Rs m | 6,936 | 14,385 | 12,142 | 18,002 | 12,771 |
GLAND PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 1,851 | 7,009 | 6,049 | 7,908 | 3,640 | |
From Investments | Rs m | -3,141 | -7,661 | -15,240 | -10,026 | 12,082 | |
From Financial Activity | Rs m | -29 | -69 | 12,385 | 349 | 149 | |
Net Cashflow | Rs m | -1,364 | -669 | 3,230 | -1,736 | 15,901 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Yiu Kwan Stanley Lau | COMP SEC: P Sampath Kumar | YEAR OF INC: 1978 | BSE CODE: 543245 | FV (Rs): 1 | DIV YIELD (%): - |
Read: GLAND PHARMA 2022-23 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare GLAND PHARMA With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.